The Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of sodium thiosulfate within its marketing authorisation for preventing hearing loss in people with cancer who are under 18 and having cisplatin chemotherapy.
Please note that following advice received from the company the timelines for this appraisal are to be confirmed. We hope to have a further update for you in due course.